• Illumina, Inc. recently secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive in vitro diagnostic test, effective January 1, 2026, at a Clinical Laboratory Fee Schedule rate of US$2,989.55 under PLA code 0543U, broadening access to comprehensive genomic profiling in oncology care.
• This decision not only supports wider use of precision oncology but also encourages more laboratories of varying sizes to bring FDA-approved genomic testing in-house, reinforcing Illumina’s role in clinical genomics alongside its expanding multiomics and proteomics capabilities.
• We’ll now examine how CMS reimbursement for TruSight Oncology Comprehensive shapes Illumina’s investment narrative, particularly its growing clinical genomics footprint.

Find companies with promising cash flow potential yet trading below their fair value.

What Is Illumina's Investment Narrative?

To own Illumina today, you have to believe in a long-term shift from research-centric sequencing to broad clinical adoption across oncology, multiomics and now proteomics. The CMS reimbursement for TruSight Oncology Comprehensive fits squarely into that story, because it gives Illumina an FDA-approved, fully reimbursed cancer test with a clear US$2,989.55 fee schedule and a defined PLA code, which can matter for nearer term revenue mix and visibility. Paired with the SomaLogic acquisition and Illumina Connected Multiomics launch, the near term catalysts increasingly cluster around clinical genomics uptake, proteomics integration and proof that these platforms can scale without eroding margins. At the same time, the stock already trades on a rich earnings multiple after a strong 3 month run, so execution risk on new products and integration now sits front and center.

However, there is an important risk around execution and valuation that investors should not ignore. Despite retreating, Illumina's shares might still be trading 20% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community currently span roughly US$102 to US$182 per share, underlining how differently retail investors are thinking about Illumina. When you set that against the emerging clinical genomics catalysts and integration risk from SomaLogic, it becomes clear that understanding these diverging views could be just as important as tracking the headlines.

Explore 4 other fair value estimates on Illumina - why the stock might be worth as much as 25% more than the current price!

Build Your Own Illumina Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.